News and Events
Alzheimer’s disease is the leading cause of dementia in the U.S., with approximately 5.4 million currently affected and an estimated 16 million by 2050. Damage to the brain from Alzheimer’s disease occurs years before patients exhibit symptoms. Attempted therapies have been unsuccessful largely because there is no measurable indicator — or biomarker — for Alzheimer’s disease before it is already symptomatic and advanced.
Congratulations to Dr. Lisa Coles, along with Drs. Seaquist, Öz, Moheet, Mangia, and Eberly, on being elected to membership in the Office of Academic Clinical Affairs (OACA) Academy for Excellence in Team Science! This Academy is intended to acknowledge the valuable and significant contributions made by an exemplar interdisciplinary team conducting biomedical or health care research to address significant health challenges.
Congratulations to Irene Vuu: On August 13 Irene Vuu, PharmD, ECP graduate student and mentee of Jim Cloyd successfully defended her PhD dissertation entitled “Development of Parenteral Drugs for the Treatment of Seizure Emergencies.” Her presentation was well organized, clearly and articulately delivered, and included some exciting data.
Flu season is here and can last until May. The Centers for Disease Control and Prevention recommends people should get the flu vaccine in October.
Ann Philbrick with the University of Minnesota talks about the flu vaccine and the health benefits of getting routine immunizations.
Q: What is the purpose of the flu vaccine?
Dr. Angela Birnbaum's interview with MedicalResearch.com
MedicalResearch.com: What is the background for this study?
While oral cannabidiol (CBD) capsules were approved by the U.S. Food and Drug Administration (FDA) for use in patients with seizures in 2018, very little was known about the effect of food on CBD absorption.
More than 50 percent of physicians experience burnout. One suggested path toward reducing the rate of burnout has been to examine how teamwork can improve satisfaction on primary care teams.
Use of a class of pain drugs called gabapentinoids has increased more than three-fold between 2002 and 2015. Gabapentinoids treat epilepsy, burning pain and neuropathic pain associated with diabetes, fibromyalgia, anxiety and restless legs syndrome.